Search results
Results from the WOW.Com Content Network
“Yesterday I found out from my sister, who found out from her hairdresser, that OGX Shampoo is facing a class-action lawsuit,” one TikTok user said. “[The products] have a chemical called ...
(Reuters) -A state judge in Oregon has overturned a jury's $260 million verdict against Johnson & Johnson in a lawsuit brought by a woman who said she got mesothelioma, a deadly cancer linked to ...
In addition to Johnson & Johnson, the lawsuit also targeted American International Industries, another defendant in the case. Both companies were found negligent and liable for Perry’s illness, with the jury awarding $32.6 million in compensatory damages and $30.7 million in punitive damages.
Johnson & Johnson on Wednesday said it plans to pay $6.5 billion over 25 years to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer ...
William Mark Lanier (born October 20, 1960 [1]) is an American trial lawyer and founder and CEO of the Lanier Law Firm. He has led a number of high-profile product litigation suits resulting in billions of dollars in damages, including Johnson & Johnson baby powder and Merck & Co.'s Vioxx drug.
Johnson & Johnson agreed to pay $1.391 billion to resolve false claims resulting from its off-label promotion of Risperdal, Invega and Natrecor. Risperdal was approved only to treat schizophrenia, yet Janssen, a Johnson and Johnson (J&J) subsidiary, promoted Risperdal to physicians and other prescribers who treated elderly dementia patients by ...
Johnson & Johnson has twice been unsuccessful in using a controversial bankruptcy tactic to contain lawsuits alleging its baby powder caused cancer. The third time, J&J said, will be different.
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.